The importance of biomarkers to optimize drug delivery
Rikki N Waterhouse
Waterhouse Imaging and Biomarker Consultants, USA
: J Addict Behav Ther Rehabil
Abstract
This presentation will highlight the use of imaging biomarkers to facilitate and optimize drug delivery in preclinical and clinical settings. A brief history of the field will be presented, followed by a clear delineation of what can be learned by translational and early clinical applications along with how to recognize which imaging modality is best in a given case, and how to confirm when such techniques may or may not be appropriate. How to utilize site-specific or metabolic positron emission tomography (PET) and single photo emission computed tomography (SPECT) probes, or in some cases (magnetic resonance imaging (MRI) techniques to address target engagement, mechanism of action, and target occupancy will be highlighted. How and when to incorporate radiopharmaceutical probe development into a drug development or delivery program will also be discussed. The presentation will end with specific examples to highlight learning points.
Biography
Rikki Waterhouse has 30 years’ experience in biomedical imaging strategies, including 15 years in academic and government labs and 15 years in pharmaceutical companies. She specializes in preclinical and clinical imaging as applied to drug development, and holds expertise in probe development for positron emission tomography and single photo emission computed tomography (SPECT) applications. She is recently Founder of Waterhouse Imaging and Biomarker Consultants, LLC (WIBC). WIBC provides professional advice on comprehensive and translational biomarker strategies and also services such as writing preclinical and clinical protocols, contracts and regulatory documents and oversight of CRO activities.
E-mail: wibc2016@gmail.com
